Endocyte Inc. develo receptor-targeted therapeutics for the treatment of cancer and autoimmune diseases. Endocyte has three compounds in Food and Drug Administration-regulated clinical trials: EC20, a targeted diagnostic agent that is in Phase II studie EC17, a targeted-hapten therapy that is in Phase I studie and EC145, a targeted cytotoxic agent that is in phase I studies. Endocyte has lice ed its vitamin-targeting technology to Bristol-Myers Squi to target Bristol-Myers Squi \'s proprietary epothilone cancer chemotherapeutic agents.
英文原文链接参见：http://www.newswise.com/articles/view/523362/#imagetop